MA57000B1 - Dérivés d'alpha-d-galactopyranoside - Google Patents
Dérivés d'alpha-d-galactopyranosideInfo
- Publication number
- MA57000B1 MA57000B1 MA57000A MA57000A MA57000B1 MA 57000 B1 MA57000 B1 MA 57000B1 MA 57000 A MA57000 A MA 57000A MA 57000 A MA57000 A MA 57000A MA 57000 B1 MA57000 B1 MA 57000B1
- Authority
- MA
- Morocco
- Prior art keywords
- diyl
- alpha
- compounds
- formula
- galactopyranoside
- Prior art date
Links
- -1 4,5-dihydroisoxazol-3,5-diyl Chemical group 0.000 abstract 8
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000000802 Galectin 3 Human genes 0.000 abstract 1
- 108010001517 Galectin 3 Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/12—Triazine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2019073063 | 2019-08-29 | ||
| PCT/EP2020/074121 WO2021038068A1 (en) | 2019-08-29 | 2020-08-28 | Alpha-d-galactopyranoside derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA57000B1 true MA57000B1 (fr) | 2024-03-29 |
Family
ID=72561746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA57000A MA57000B1 (fr) | 2019-08-29 | 2020-08-28 | Dérivés d'alpha-d-galactopyranoside |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US12319672B2 (https=) |
| EP (1) | EP4021904B1 (https=) |
| JP (1) | JP7612669B2 (https=) |
| KR (1) | KR102824799B1 (https=) |
| CN (1) | CN114585619B (https=) |
| AU (1) | AU2020338816B2 (https=) |
| BR (1) | BR112022003562A2 (https=) |
| CA (1) | CA3148365A1 (https=) |
| ES (1) | ES2972551T3 (https=) |
| HR (1) | HRP20240297T1 (https=) |
| HU (1) | HUE066221T2 (https=) |
| IL (1) | IL290815B2 (https=) |
| MA (1) | MA57000B1 (https=) |
| MX (1) | MX2022002339A (https=) |
| MY (1) | MY207787A (https=) |
| PH (1) | PH12022550436A1 (https=) |
| PL (1) | PL4021904T3 (https=) |
| RS (1) | RS65294B1 (https=) |
| SA (1) | SA522431777B1 (https=) |
| TW (1) | TWI864085B (https=) |
| UA (1) | UA129205C2 (https=) |
| WO (1) | WO2021038068A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114206893A (zh) | 2019-08-09 | 2022-03-18 | 爱杜西亚药品有限公司 | (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物 |
| WO2021028323A1 (en) | 2019-08-09 | 2021-02-18 | Idorsia Pharmaceuticals Ltd | (2-acetamidyl)thio-beta-d-galactopyranoside derivatives |
| MA56883B1 (fr) | 2019-08-15 | 2025-04-30 | Idorsia Pharmaceuticals Ltd | Dérivés de 2-hydroxycycloalcane-1-carbamoyle |
| US12312362B2 (en) | 2020-10-06 | 2025-05-27 | Idorsia Pharmaceuticals Ltd | Spiro derivatives of Alpha-D-galactopyranosides |
| EP4237419A1 (en) | 2020-11-02 | 2023-09-06 | Idorsia Pharmaceuticals Ltd | Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives |
| CN116806219A (zh) * | 2021-02-09 | 2023-09-26 | 爱杜西亚药品有限公司 | 羟基杂环烷-氨甲酰基衍生物 |
| RS67032B1 (sr) * | 2021-03-03 | 2025-08-29 | Idorsia Pharmaceuticals Ltd | Alfa-d-galaktopiranozidni derivati supstituisani triazolil-metilom |
| US20240287121A1 (en) * | 2021-05-28 | 2024-08-29 | Glycomimetics, Inc. | Galectin-3 inhibiting c-glycoside oximes |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100172D0 (sv) | 2001-01-22 | 2001-01-22 | Ulf Nilsson | New inhibitors against galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| SE0401301D0 (sv) * | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| DK2906227T3 (en) | 2012-10-10 | 2018-12-10 | Galectin Therapeutics Inc | GALACTOSE-CONTAINING CARBOHYDRATE COMPOUNDS FOR THE TREATMENT OF DIABETIC Nephropathy |
| CN104755088A (zh) | 2012-10-31 | 2015-07-01 | 格莱克特生物技术公司 | 半乳凝集素-3的半乳糖苷抑制剂及其用于治疗肺纤维化的应用 |
| EP2919802A4 (en) | 2012-11-15 | 2016-09-14 | Univ Tufts | METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER |
| CA2970062C (en) | 2015-01-30 | 2023-02-28 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| PL3456717T3 (pl) | 2015-07-06 | 2021-10-25 | Gilead Sciences, Inc. | Pochodna 4,6-diaminochinolino-3-karbonitrylu jako modulator cot (cancer osaka thyroid) do leczenia choroby zapalnej |
| CA3025867A1 (en) | 2016-07-12 | 2018-01-18 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| EP3621973A4 (en) | 2017-05-12 | 2021-10-27 | Galectin Sciences, LLC | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES AND USES THEREOF |
| KR20200015528A (ko) | 2017-05-12 | 2020-02-12 | 갈랙틴 사이언시즈, 엘엘씨 | 전신 인슐린 내성 질환의 치료용 화합물 및 그의 용도 |
| WO2019067702A1 (en) | 2017-09-27 | 2019-04-04 | Bristol-Myers Squibb Company | INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3 |
| US11072626B2 (en) | 2017-10-11 | 2021-07-27 | Bristol-Myers Squibb Company | Small molecule inhibitors of Galectin-3 |
| CA3080128A1 (en) | 2017-10-31 | 2019-05-09 | Galectin Sciences, Llc | Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof |
| CN113286632A (zh) | 2018-10-15 | 2021-08-20 | 格莱克特生物技术公司 | 半乳糖凝集素的半乳糖苷抑制剂前药 |
| JP2022508720A (ja) | 2018-10-15 | 2022-01-19 | ガレクト バイオテック エービー | ガレクチンのガラクトシド阻害剤 |
| WO2020104335A1 (en) | 2018-11-21 | 2020-05-28 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| US12269819B2 (en) | 2019-04-10 | 2025-04-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of Galectin-3 |
| JP7674276B2 (ja) | 2019-07-03 | 2025-05-09 | ガレクト バイオテック エービー | ガレクチンの新規なガラクトシド阻害剤 |
| WO2021004940A1 (en) | 2019-07-05 | 2021-01-14 | Galecto Biotech Ab | Novel galactoside inhibitor of galectins |
| WO2021028323A1 (en) | 2019-08-09 | 2021-02-18 | Idorsia Pharmaceuticals Ltd | (2-acetamidyl)thio-beta-d-galactopyranoside derivatives |
| CN114206893A (zh) | 2019-08-09 | 2022-03-18 | 爱杜西亚药品有限公司 | (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物 |
| MA56883B1 (fr) | 2019-08-15 | 2025-04-30 | Idorsia Pharmaceuticals Ltd | Dérivés de 2-hydroxycycloalcane-1-carbamoyle |
| US12312362B2 (en) | 2020-10-06 | 2025-05-27 | Idorsia Pharmaceuticals Ltd | Spiro derivatives of Alpha-D-galactopyranosides |
| EP4237419A1 (en) | 2020-11-02 | 2023-09-06 | Idorsia Pharmaceuticals Ltd | Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives |
| CN116806219A (zh) | 2021-02-09 | 2023-09-26 | 爱杜西亚药品有限公司 | 羟基杂环烷-氨甲酰基衍生物 |
| RS67032B1 (sr) | 2021-03-03 | 2025-08-29 | Idorsia Pharmaceuticals Ltd | Alfa-d-galaktopiranozidni derivati supstituisani triazolil-metilom |
-
2020
- 2020-08-28 CN CN202080060134.6A patent/CN114585619B/zh active Active
- 2020-08-28 PL PL20775188.4T patent/PL4021904T3/pl unknown
- 2020-08-28 PH PH1/2022/550436A patent/PH12022550436A1/en unknown
- 2020-08-28 TW TW109129635A patent/TWI864085B/zh active
- 2020-08-28 KR KR1020227009790A patent/KR102824799B1/ko active Active
- 2020-08-28 EP EP20775188.4A patent/EP4021904B1/en active Active
- 2020-08-28 JP JP2022512854A patent/JP7612669B2/ja active Active
- 2020-08-28 ES ES20775188T patent/ES2972551T3/es active Active
- 2020-08-28 MY MYPI2022001043A patent/MY207787A/en unknown
- 2020-08-28 BR BR112022003562A patent/BR112022003562A2/pt unknown
- 2020-08-28 US US17/638,799 patent/US12319672B2/en active Active
- 2020-08-28 HU HUE20775188A patent/HUE066221T2/hu unknown
- 2020-08-28 HR HRP20240297TT patent/HRP20240297T1/hr unknown
- 2020-08-28 RS RS20240319A patent/RS65294B1/sr unknown
- 2020-08-28 AU AU2020338816A patent/AU2020338816B2/en active Active
- 2020-08-28 WO PCT/EP2020/074121 patent/WO2021038068A1/en not_active Ceased
- 2020-08-28 CA CA3148365A patent/CA3148365A1/en active Pending
- 2020-08-28 UA UAA202201022A patent/UA129205C2/uk unknown
- 2020-08-28 MA MA57000A patent/MA57000B1/fr unknown
- 2020-08-28 MX MX2022002339A patent/MX2022002339A/es unknown
- 2020-08-28 IL IL290815A patent/IL290815B2/en unknown
-
2022
- 2022-02-27 SA SA522431777A patent/SA522431777B1/ar unknown
-
2025
- 2025-04-29 US US19/193,332 patent/US20250257056A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL290815A (en) | 2022-04-01 |
| CN114585619B (zh) | 2024-09-27 |
| SA522431777B1 (ar) | 2024-04-30 |
| TWI864085B (zh) | 2024-12-01 |
| IL290815B2 (en) | 2025-08-01 |
| ES2972551T3 (es) | 2024-06-13 |
| US20220281855A1 (en) | 2022-09-08 |
| MY207787A (en) | 2025-03-19 |
| AU2020338816A1 (en) | 2022-04-14 |
| EP4021904C0 (en) | 2024-01-03 |
| EP4021904A1 (en) | 2022-07-06 |
| UA129205C2 (uk) | 2025-02-05 |
| RS65294B1 (sr) | 2024-04-30 |
| WO2021038068A1 (en) | 2021-03-04 |
| US20250257056A1 (en) | 2025-08-14 |
| PL4021904T3 (pl) | 2024-05-13 |
| HUE066221T2 (hu) | 2024-07-28 |
| IL290815B1 (en) | 2025-04-01 |
| PH12022550436A1 (en) | 2022-12-19 |
| KR102824799B1 (ko) | 2025-06-24 |
| KR20220053622A (ko) | 2022-04-29 |
| MX2022002339A (es) | 2022-04-06 |
| JP7612669B2 (ja) | 2025-01-14 |
| HRP20240297T1 (hr) | 2024-05-10 |
| CN114585619A (zh) | 2022-06-03 |
| EP4021904B1 (en) | 2024-01-03 |
| TW202122092A (zh) | 2021-06-16 |
| JP2022546029A (ja) | 2022-11-02 |
| AU2020338816B2 (en) | 2026-01-08 |
| BR112022003562A2 (pt) | 2022-05-24 |
| CA3148365A1 (en) | 2021-03-04 |
| US12319672B2 (en) | 2025-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA57000B1 (fr) | Dérivés d'alpha-d-galactopyranoside | |
| MA56883B1 (fr) | Dérivés de 2-hydroxycycloalcane-1-carbamoyle | |
| MA67365B1 (fr) | Dérivés de benzisoxazole sulfonamide | |
| MA54653B1 (fr) | Modulateurs du récepteur de cxcr7 pipéridine | |
| MA28747B1 (fr) | Dérivés de pyridine | |
| MA29926B1 (fr) | Derives de pyrazine | |
| MA30142B1 (fr) | Agonistes du recepteur de neuropeptide-2 | |
| MA27990A1 (fr) | Derives de piperazine pour le traitement d'infections par le vih | |
| MA27560A1 (fr) | Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation | |
| MA58181B1 (fr) | Composés tricycliques substitués | |
| MA52360B1 (fr) | Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines | |
| MA27774A1 (fr) | Inhibiteurs de phosphatidylinositol 3-kinase | |
| MA27559A1 (fr) | Nouveaux derives de fluorglycoside aromatiques, produits pharmaceutiques contenant ces composes et leur utilisation | |
| TN2009000450A1 (fr) | Derives de pyridine | |
| MA55046B1 (fr) | Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2 | |
| MA27796A1 (fr) | Composes n-heterocycliques condenses et leur utilisation comme antagonistes des recepteurs de crf | |
| MA26857A1 (fr) | Azaindoles | |
| MA49127B1 (fr) | Dérivés d'indole n-substitués | |
| MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA27389A1 (fr) | Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs. | |
| MA63589B1 (fr) | Dérivés d'alpha-d-galactopyranoside substitués par triazolyl-méthyle | |
| TNSN05073A1 (fr) | Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase | |
| MA31761B1 (fr) | Nouveaux inhibiteurs de seh et leur utilisation | |
| MA49956B1 (fr) | Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak | |
| CA3156303A1 (en) | 5-fluoronicotinamide derivatives and uses thereof |